[go: up one dir, main page]

NO951775L - Nye 3,3-difenylpropylaminer, deres anvendelse og fremstilling - Google Patents

Nye 3,3-difenylpropylaminer, deres anvendelse og fremstilling

Info

Publication number
NO951775L
NO951775L NO951775A NO951775A NO951775L NO 951775 L NO951775 L NO 951775L NO 951775 A NO951775 A NO 951775A NO 951775 A NO951775 A NO 951775A NO 951775 L NO951775 L NO 951775L
Authority
NO
Norway
Prior art keywords
compounds
diphenylpropylamines
methyl
preparation
formula
Prior art date
Application number
NO951775A
Other languages
English (en)
Other versions
NO951775D0 (no
NO305477B1 (no
Inventor
Rolf Arne Johansson
Pinchas Moses
Lisbeth Nilverbant
Bengt Aake Sparf
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20387730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO951775(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO951775D0 publication Critical patent/NO951775D0/no
Publication of NO951775L publication Critical patent/NO951775L/no
Publication of NO305477B1 publication Critical patent/NO305477B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
NO951775A 1992-11-06 1995-05-05 Nye 3,3-difenylpropylaminer, farmas°ytiske preparater inneholdende slike forbindelser, og deres anvendelse NO305477B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203318A SE9203318D0 (sv) 1992-11-06 1992-11-06 Novel 3,3-diphenylpropylamines, their use and preparation
PCT/SE1993/000927 WO1994011337A1 (en) 1992-11-06 1993-11-05 Novel 3,3-diphenylpropylamines, their use and preparation

Publications (3)

Publication Number Publication Date
NO951775D0 NO951775D0 (no) 1995-05-05
NO951775L true NO951775L (no) 1995-05-05
NO305477B1 NO305477B1 (no) 1999-06-07

Family

ID=20387730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951775A NO305477B1 (no) 1992-11-06 1995-05-05 Nye 3,3-difenylpropylaminer, farmas°ytiske preparater inneholdende slike forbindelser, og deres anvendelse

Country Status (15)

Country Link
US (4) USRE40851E1 (no)
EP (1) EP0667852B1 (no)
JP (1) JP3343256B2 (no)
AT (1) ATE164828T1 (no)
AU (1) AU672458B2 (no)
CA (1) CA2148827C (no)
DE (1) DE69317898T2 (no)
DK (1) DK0667852T3 (no)
ES (1) ES2117155T3 (no)
FI (1) FI120256B (no)
HK (1) HK1006349A1 (no)
HU (1) HU224916B1 (no)
NO (1) NO305477B1 (no)
SE (1) SE9203318D0 (no)
WO (1) WO1994011337A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6207681B1 (en) 1996-07-01 2001-03-27 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R)-trihexyphenidyl
EP0948964B1 (en) * 1996-12-02 2003-04-02 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
PT1039882E (pt) 1998-08-27 2011-01-03 Pfizer Health Ab Formulação terapêutica para administrar tolterodina com libertação controlada
SK6412002A3 (en) 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
CA2404280A1 (en) 2000-03-24 2002-09-23 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid .delta. receptor agonists
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
CN1536986B (zh) * 2001-03-27 2012-07-04 沃纳奇尔科特(爱尔兰)有限公司 用于抗微生物剂给药的阴道内药物递送装置
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
CA2464223C (en) * 2001-10-26 2009-05-26 Pharmacia & Upjohn Company Quarternary ammonium compounds and their use as antimuscarinic agents
MXPA04003806A (es) * 2001-11-05 2005-04-08 Upjohn Co Aerosol antimuscarinico.
JP2005512995A (ja) * 2001-11-09 2005-05-12 ファイザー ヘルス アーベー 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト
AU2002360717A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Controlled release dosage form having improved drug release properties
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7005449B2 (en) * 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
ATE419236T1 (de) * 2002-07-08 2009-01-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
NZ539425A (en) 2002-11-13 2007-11-30 Chiron Corp Methods of treating cancer and related methods
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1618091A1 (en) * 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) * 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2004096751A1 (en) 2003-04-25 2004-11-11 Pharmacia & Upjohn Company Llc Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity
ATE545627T1 (de) * 2003-05-23 2012-03-15 Bridge Pharma Inc Glattmuskelspasmolytika
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
JP5250205B2 (ja) * 2003-12-24 2013-07-31 シプラ・リミテッド トルテロジン、その組成物及び使用、及びその製造方法
BRPI0507891A (pt) 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
EP1836156A1 (en) * 2005-01-10 2007-09-26 Teva Gyogyszergyar Reszvenytarsasag Substantially pure tolterodine tartrate and process for preparing thereof
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
NZ564144A (en) 2005-05-13 2009-11-27 Novartis Ag Methods for treating drug resistant cancer
EP1965863A2 (en) * 2005-12-20 2008-09-10 Pfizer Products Inc. Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
MEP9608A (en) 2006-03-20 2010-06-10 Pfizer Ltd Amine derivatives
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
WO2007137799A1 (en) * 2006-05-31 2007-12-06 Schwarz Pharma Ltd. New synthesis of substituted hydroxymethyl phenols
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
WO2007140986A1 (en) 2006-06-09 2007-12-13 Schwarz Pharma Ltd Synthesis of phenolic esters of hydroxymethyl phenols
WO2007144097A1 (en) 2006-06-12 2007-12-21 Schwarz Pharma Ag New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
BRPI0713314A2 (pt) 2006-06-20 2012-03-06 Lek Pharmaceuticals D.D. Processo para a preparação de 3-(2-hidróxi-5-fenil substituído)-n-alquil-3-fenilpropilaminas
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
PL2416761T3 (pl) * 2009-05-11 2015-07-31 Ratiopharm Gmbh Desfezoterodyna w postaci soli kwasu winowego
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
SI2281801T1 (sl) * 2009-07-27 2014-04-30 Crystal Pharma, S.A.U. Postopek za pridobivanje 3,3-diphenilpropilamina
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
TWI520732B (zh) 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
CA2873721C (en) 2012-05-04 2021-06-22 Crystal Pharma, S.A.U. Process for the preparation of optically active 3,3-diphenylpropylamines
EP2760822B1 (en) 2012-06-14 2016-03-23 ratiopharm GmbH Desfesoterodine salts
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2016148444A1 (ko) * 2015-03-17 2016-09-22 제이더블유중외제약 주식회사 신규 데스페소테로딘 유도체, 이의 약제학적으로 허용되는 염 및 이를 포함하는 약제학적 조성물
WO2017137955A1 (en) 2016-02-14 2017-08-17 Celestis Pharmaceuticals Pvt. Ltd. Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (no) 1962-11-15
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
GB1169944A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
US4139537A (en) 1976-06-29 1979-02-13 Cooper Laboratories, Inc. 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
WO1994011337A1 (en) 1994-05-26
FI952179A0 (fi) 1995-05-05
JPH08503208A (ja) 1996-04-09
CA2148827A1 (en) 1994-05-26
ATE164828T1 (de) 1998-04-15
SE9203318D0 (sv) 1992-11-06
ES2117155T3 (es) 1998-08-01
FI120256B (fi) 2009-08-31
USRE39667E1 (en) 2007-05-29
AU5438094A (en) 1994-06-08
HK1006349A1 (en) 1999-02-19
US5559269A (en) 1996-09-24
CA2148827C (en) 2005-01-04
DE69317898D1 (de) 1998-05-14
FI952179A (fi) 1995-05-05
EP0667852A1 (en) 1995-08-23
NO951775D0 (no) 1995-05-05
NO305477B1 (no) 1999-06-07
USRE40851E1 (en) 2009-07-14
HU224916B1 (en) 2006-04-28
JP3343256B2 (ja) 2002-11-11
AU672458B2 (en) 1996-10-03
HUT72742A (en) 1996-05-28
US5686464A (en) 1997-11-11
DK0667852T3 (da) 1999-01-11
DE69317898T2 (de) 1998-10-15
HU9501329D0 (en) 1995-06-28
EP0667852B1 (en) 1998-04-08

Similar Documents

Publication Publication Date Title
NO951775L (no) Nye 3,3-difenylpropylaminer, deres anvendelse og fremstilling
ES2029384T4 (es) Procedimiento para preparar nuevas 3,3-difenilpropilaminas.
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
AU4616893A (en) New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them
HK1023346A1 (en) Novel substituted tetrahyropyridine derivatives, method of preparation and pharmaceutical compositions containing them
DE3381885D1 (de) Piperidinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
AU5511394A (en) New (cyclohexyl)alkene compounds, processes for preparing them and pharmaceutical compositions containing them
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK1K Patent expired